Department of Neurosurgery, Mayo Clinic College of Medicine, Jacksonville, FL, United States.
Department of Neurosurgery, Mayo Clinic College of Medicine, Jacksonville, FL, United States.
EBioMedicine. 2017 Jul;21:94-103. doi: 10.1016/j.ebiom.2017.06.020. Epub 2017 Jun 21.
Glioblastoma (GBM) is the most aggressive primary brain tumor in adults. The mechanisms that confer GBM cells their invasive behavior are poorly understood. The electroneutral Na-K-2Cl co-transporter 1 (NKCC1) is an important cell volume regulator that participates in cell migration. We have shown that inhibition of NKCC1 in GBM cells leads to decreased cell migration, in vitro and in vivo. We now report on the role of NKCC1 on cytoskeletal dynamics. We show that GBM cells display a significant decrease in F-actin content upon NKCC1 knockdown (NKCC1-KD). To determine the potential actin-regulatory mechanisms affected by NKCC1 inhibition, we studied NKCC1 protein interactions. We found that NKCC1 interacts with the actin-regulating protein Cofilin-1 and can regulate its membrane localization. Finally, we analyzed whether NKCC1 could regulate the activity of the small Rho-GTPases RhoA and Rac1. We observed that the active forms of RhoA and Rac1 were decreased in NKCC1-KD cells. In summary, we report that NKCC1 regulates GBM cell migration by modulating the cytoskeleton through multiple targets including F-actin regulation through Cofilin-1 and RhoGTPase activity. Due to its essential role in cell migration NKCC1 may serve as a specific therapeutic target to decrease cell invasion in patients with primary brain cancer.
胶质母细胞瘤(GBM)是成人中最具侵袭性的原发性脑肿瘤。赋予 GBM 细胞侵袭行为的机制尚未完全清楚。电中性的 Na-K-2Cl 协同转运蛋白 1(NKCC1)是一种重要的细胞体积调节剂,参与细胞迁移。我们已经表明,在 GBM 细胞中抑制 NKCC1 会导致体外和体内细胞迁移减少。我们现在报告 NKCC1 在细胞骨架动力学中的作用。我们发现,在 NKCC1 敲低(NKCC1-KD)后,GBM 细胞的 F- 肌动蛋白含量明显减少。为了确定 NKCC1 抑制影响的潜在肌动蛋白调节机制,我们研究了 NKCC1 蛋白相互作用。我们发现 NKCC1 与肌动蛋白调节蛋白 Cofilin-1 相互作用,并可以调节其膜定位。最后,我们分析了 NKCC1 是否可以调节小 Rho-GTPases RhoA 和 Rac1 的活性。我们观察到 NKCC1-KD 细胞中 RhoA 和 Rac1 的活性形式减少。总之,我们报告 NKCC1 通过多种靶标调节细胞骨架来调节 GBM 细胞迁移,包括通过 Cofilin-1 调节 F-肌动蛋白和 RhoGTPase 活性。由于其在细胞迁移中的重要作用,NKCC1 可能成为减少原发性脑癌患者细胞侵袭的特定治疗靶点。